Musella Martina, Manic Gwenola, De Maria Ruggero, Vitale Ilio, Sistigu Antonella
Unit of Cellular Networks and Molecular Therapeutic Targets, Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy.
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Oncoimmunology. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424. eCollection 2017.
If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.
如果说癌症治疗有什么重大新希望的话，那就是免疫系统。固有免疫和适应性免疫既可以促进肿瘤发生，也可以减弱肿瘤发生，因此对治疗结果可能产生相反的影响。I型干扰素（IFNs）最初被描述为强效抗病毒物质，很快就被认为是肿瘤与免疫系统相互作用的核心协调因子。I型干扰素由肿瘤细胞和免疫细胞产生，并作用于这些细胞，既具有保护宿主的作用，也具有促进肿瘤的作用。在此，我们讨论I型干扰素在感染性疾病和癌症中的作用，强调其双重作用，并凸显深入了解其潜在机制以重塑我们利用I型干扰素进行治疗的方式的重要性。
